Association of hypoxia-inducible factors 1α and 2α with activated angiogenic pathways and prognosis in patients with endometrial carcinoma

Cancer

Volumn 95, Issue 5, 2002, Pages 1055-1063

  Sivridis, Efthimios ^a   Giatromanolaki, Alexandra ^a   Gatter, Kevin C ^b   Harris, Adrian L ^b   Koukourakis, Michael I ^a,c  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c Tumor and Angiogenesis Research Group Alexandroupolis   (Greece)

Author keywords

Angiogenesis; Endometrial carcinoma; Hypoxia inducible factor ; Prognosis; Vascular endothelial growth factor

Indexed keywords

ANGIOGENIC FACTOR; ESTROGEN RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53; REGULATOR PROTEIN; THYMIDINE PHOSPHORYLASE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ADULT; ANGIOGENESIS; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CELL HYPOXIA; CELL NUCLEUS; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION COEFFICIENT; CYTOPLASM; ENDOMETRIUM CARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; MICROVASCULATURE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADENOCARCINOMA; ADULT; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; DNA-BINDING PROTEINS; ENDOMETRIAL NEOPLASMS; ENDOTHELIAL GROWTH FACTORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; LYMPHOKINES; NEOVASCULARIZATION, PATHOLOGIC; NUCLEAR PROTEINS; PROGNOSIS; THYMIDINE PHOSPHORYLASE; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0036721256     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10774     Document Type: Article

References (37)

1. The molecular basis of hypoxia response pathway: Tumour hypoxia as a therapy target
2. Hypoxia, HIF-1, and the pathophysiology of common human disease
3. Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway
4. Hypoxia-inducible nuclear factors bind to an enhancer element located 3′ to the human erythropoietin gene
5. Expression of hypoxia-inducible factor-1alpha: A novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer
6. Hypoxia inducible factor (HIF-1a and HIF-2a) expression in early esophageal cancer and response to photodynamic therapy and radiotherapy
7. Relation of hypoxia inducible factor 1α and 2α in operable non-small cell lung cancer to angiogenic/molecular profile of tumors and survival
8. Dating the endometrial biopsy
9. Endometrial hyperplasia, metaplasia and carcinoma
10. Endometrial carcinoma
11. The expression and distribution of the hypoxia inducible factors HIF-1a and HIF-2a in normal human tissues, cancers and tumor associated macrophages
12. Endometrial carcinoma: Association of steroid hormone receptor expression with low angiogenesis and bcl-2 expression
13. Bcl-2 and p53 expression in stage I endometrial carcinoma
14. Expression of VEGF in routinely fixed material using a new monoclonal antibody VG1
15. Vascular endothelial growth factor as a marker of tumor endothelium
16. The angiogenic "vascular endothelial growth factor/fll-1(KDR) receptor" pathway: Prognostic and therapeutic implications
17. Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in normal tissues: An immunohistochemical study
18. Thymidine phosphorylase expression in endometrial carcinomas
19. Patterns of episialin/MUC1 expression in endometrial carcinomas and prognostic relevance
20. Von-Hippel-Lindau syndrome: Target for antivascular endothelial growth factor (VEGF) receptor therapy
21. Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element
22. Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2
23. Loss of PTEN facilitates HIF-1-mediated gene expression
24. Blockade of the vascular endothelial growth factor stress response increases the antitumor effect of ionizing radiation
25. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human xenografts
26. Angiogenesis, thymidine phosphorylase and resistance of squamous cell head and neck cancer to cytotoxic and radiation therapy
27. Overexpression of hypoxia-inducible factor la in common human cancers and their metastases
28. Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in earlystage invasive cervical cancer
29. Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis
30. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: Implications for tumor angiogenesis and therapeutics
31. Insulin induces transcription of target genes through the hypoxia-inducible factor HIF1alpha/ARNT
32. Vascular endothelial growth factor is modulated in vascular muscle cells by estradiol, tamoxifen and hypoxia
33. Intratumoral angiogenesis: A new prognostic indicator for Stage I endometrial adenocarcinomas?
34. Angiogenic cooperation of VEGF and stromal cell TP in endometrial carcinomas
35. Induction of endothelial PAS domain protein-1 by hypoxia: Characterization and comparison with hypoxia-inducible factor-1alpha
36. Vascular patterns of tumors: Scanning and transmission electron microscopic studies on human xenografts
37. Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: Clinical implications